



April 29, 2024

RE: ADHD Medications and Nuvigil® Coverage Changes Effective May 13, 2024

The following changes will take effect May 13, 2024. Complete prior authorization (PA) criteria can be found on the OHCA website at www.oklahoma.gov/ohca/pa. Pharmacy prior authorization forms can be found on the OHCA website at <https://oklahoma.gov/ohca/rxforms>.

ADHD Medications

Changes to the ADHD medications tier chart include the following:

- Vyvanse® (lisdexamfetamine) chewable tablets and capsules will be brand preferred. Members currently utilizing generic lisdexamfetamine will need to switch to brand Vyvanse®.
- Dyanavel® XR [amphetamine extended-release (ER)] suspension will be moved to Tier-3. Current utilizers will be approved for continuation of therapy.
- Aptensio XR® (methylphenidate ER capsules) will no longer be brand preferred. Members currently utilizing brand Aptensio XR® will need to switch to generic methylphenidate ER capsules.

The specific PA requirements and tier chart for the ADHD Medications are located on the OHCA website at www.oklahoma.gov/ohca/pa in the “Central Nervous System/Behavioral Health” therapeutic category.

Nuvigil®

Nuvigil® (armodafinil) will no longer be brand preferred. Members currently utilizing brand Nuvigil® will need to submit a PA request to switch to generic armodafinil and will be approved for continuation of therapy. The specific PA requirements for the Narcolepsy Medications are located on the OHCA website at www.oklahoma.gov/ohca/pa in the “Central Nervous System/Behavioral Health” therapeutic category.

Thank you for the services you provide to Oklahomans insured by SoonerCare!

SOONERCARE PHARMACY SERVICES • PHARMACY MANAGEMENT CONSULTANTS



ADDRESS

4345 N. Lincoln Blvd.
Oklahoma City, OK 73105



WEBSITES

oklahoma.gov/ohca
mysoonerCare.org



PHONE

Admin: 405-522-7300
Helpline: 800-987-7767